Interactions of proton pump inhibitors and Helicobacter pylori in vivo

  • Andre Louis Blum
  • Jan Martinek
Part of the Milestones in Drug Therapy MDT book series (MDT)


There are multiple interactions between proton pump inhibitors (PPIs) and Helicobacter pylori in vivo. This chapter deals with two aspects: First, we discuss the effect of H. pylori on pH control by PPIs and on the clinical effectiveness of these drugs. Second, we focus on the effect of PPIs on H. pylori and on gastritis. Of special interest is the question whether long-term treatment with PPIs leads, in H. pylori-infected subjects, to the development of atrophic gastritis and associated changes, considered by some authors to represent a precancerous condition.


Proton Pump Inhibitor Pylorus Infection Intestinal Metaplasia Reflux Esophagitis Atrophic Gastritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Verdú EF, Armstrong D, Fraser R, Viani F, Iström J-P, Cederberg C, Blum AL (1995) Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36: 539–543PubMedCrossRefGoogle Scholar
  2. 2.
    Verdú EF, Armstrong D, Idström J-P, Labenz J, Stolte M, Dorta G, Börsch G, Blum AL (1995) Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 37: 743–748PubMedCrossRefGoogle Scholar
  3. 3.
    Labenz J, Tillenburg B, Peitz U, Idström J-P, Verdú EF, Stolte M, Börsch G, Blum AL (1996) Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 110: 725–732PubMedCrossRefGoogle Scholar
  4. 4.
    Martínek J, Blum AL, Stolte M, Wiesel P (1997) Effect of BY841 (INN: pumaprazole) and of omeprazole on intragastric acidity before and after cure of Helicobacter pylori infection. Gut 41:A35Google Scholar
  5. 5.
    Wurst W, Hartmann M (1996) Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med 69: 233–243PubMedGoogle Scholar
  6. 6.
    Verdú EF, Armstrong D, Sabovcikova L, Idström J-P, Cederberg C, Blum AL, Bercik P (1998) High concentrations of ammonia, but not volatile amines, in gastric juice of subjects with Helicobacter pylori infection. Helicobacter;in press Google Scholar
  7. 7.
    Bercik P, Verdú EF, Armstrong D, Cederberg C, Idström J-P, Stolte M, Blum AL (1997) Apparent increase in acid output during omeprazole after cure of H. pylori infection. Gastroenterology 112: A70Google Scholar
  8. 8.
    Gillen D, Wirz A, Neithercut W, Ardill J, McColl KEL (1998) Neutralization by ammonia cannot explain H. pylori’s potentiation of omeprazole’s efficacy. Gastroenterology 114: A132CrossRefGoogle Scholar
  9. 9.
    Furuta T, Ohashi K, Takashima M, Hanai H, Kubota T, Ishizaki T, Kaneko E (1998) CYP2C19 genotype status and effect of omeprazole on intragastrie pH. Gastroenterology 114:A127Google Scholar
  10. 10.
    Tucker GT (1994) The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 8 (Suppl 1): 33–38PubMedGoogle Scholar
  11. 11.
    Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, Jones PH, Trowell JE (1991) Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 5: 309–313PubMedCrossRefGoogle Scholar
  12. 12.
    Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH (1995) Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36: 12–16PubMedCrossRefGoogle Scholar
  13. 13.
    Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A (1992) Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against H. pylori. Antimicrob Agents Chemother 35: 490–496CrossRefGoogle Scholar
  14. 14.
    Sjöstrom JE, Kühler T, Larsson H (1997) Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother 41: 1797–1801PubMedGoogle Scholar
  15. 15.
    Sjöstrom JE, Fryklund J, Kühler T, Larsson H (1997) In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. Antimicrob Agents Chemother 40: 621–626Google Scholar
  16. 16.
    Stoschus B, Dominguez-Munoz JE, Kalhori N, Sauerbruch T, Malfertheiner P (1996) Effect of omeprazole on Helicobacter pylori urease activity in vivo. Eur J Gastroenterol Hepatol 8:811–813PubMedGoogle Scholar
  17. 17.
    Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, Spiller RC (1996). Effect of omeprazole on the distribution of metronidazole, amoxicillin and clarithromycin in human gastric juice. Gastroenterology 111:358–367PubMedCrossRefGoogle Scholar
  18. 18.
    Debets-Ossenkopp YJ, Namavar F, MacLaren DM (1995) Effect of an acidic environment on the susceptibility of H. pylori to trospectomycin and other antimicrobial agents. Eur J Microbiol Infect Dis 14: 353–355CrossRefGoogle Scholar
  19. 19.
    Anonymous (1994) NIH concensus conference. Helicobacter pylori in peptic ulcer disease. NIH concensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA 272: 65–69CrossRefGoogle Scholar
  20. 20.
    Anonymous (1997) Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41: 8–13CrossRefGoogle Scholar
  21. 21.
    Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E (1998) Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 12: 247–253PubMedCrossRefGoogle Scholar
  22. 22.
    Peterson WL (1997) The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Alimet Pharmacol Ther 11 (Suppl 1): 21–25CrossRefGoogle Scholar
  23. 23.
    Wilde MI, McTavish D (1994) Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 48: 91–132PubMedCrossRefGoogle Scholar
  24. 24.
    Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O’Morain C, Cooper BT, Kerr GD, Dixon MF, Langworthy H, Piper D (1997) One-week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 41: 735–739PubMedCrossRefGoogle Scholar
  25. 25.
    Fukuda Y (1996) Suppression of Helicobacter pylori colonisation with omeprazole. Scand J Gastroenterol 31 (Suppl 214): 54–55CrossRefGoogle Scholar
  26. 26.
    Midolo PD, Turnidge JD, Lambert JR (1997) Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro}. J Antimicrobial Chemother 39: 331–337CrossRefGoogle Scholar
  27. 27.
    Mion F, Delecluse HJ, Rousseau M, Berger F, Brazier JL, Minaire Y (1994) 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Comparison with histology. Gastroenterol Clin Biol 18: 1106–1111PubMedGoogle Scholar
  28. 28.
    Goddard AF, Logan RPH (1997) Review article: urea breath tests for detecting Helicobacter pylori. Aliment Pharmacol Ther 11: 641–649PubMedCrossRefGoogle Scholar
  29. 29.
    Rollan A, Giancaspero R, Arrese M, Figueroa C, Vollrath V, Schultz M, Duarte I, Vial P (1997) Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection after antibiotic treatment. Am J Gastroenterol 92: 1268–1274PubMedGoogle Scholar
  30. 30.
    Wyatt JI, Gray SF (1992) Detection of Helicobacter pylori by histology. In: BJ Rathbone, RV Heatley (eds) Helicobacter pylori and gastroduodenal disease. Blackwell Science Ltd, Oxford, 51–57Google Scholar
  31. 31.
    Lind T, Veldhuyzen van Zanten S, Unge P, Spiller RC, Bayerdörffer E, O’Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M et al (1996) Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1: 138–144PubMedCrossRefGoogle Scholar
  32. 32.
    Talley NJ, Janssens J, Lauritsen K, Racs I (1998) Cure of H. pylori does not abolish symptoms in non-ulcer dyspepsia: a randomized double-blind placebo controlled trial with 12 months follow-up. itAliment Pharmacol Ther;in press}Google Scholar
  33. 33.
    Blum AL, Arnold R, Koelz HR et al (1997) Treatment of functional dyspepsia (FD) with omeprazole and ranitidine. Gastroenterology 110: A73Google Scholar
  34. 34.
    Penston JG, McColl KE (1997) Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 43: 223–243PubMedCrossRefGoogle Scholar
  35. 35.
    Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E (1993) Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 104: 1356–1370PubMedGoogle Scholar
  36. 36.
    Solcia E, Fiocca R, Havu N, Dalväg A, Carlsson R (1992) Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 51 (Suppl 1): 82–92PubMedCrossRefGoogle Scholar
  37. 37.
    Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, Lückers A, Dekkers CPM, Havu N, Meuwissen SGM (1994) Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121: 161–167PubMedGoogle Scholar
  38. 38.
    Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HPM, Liedman B, Lamers CBHW, Jansen BMJ, Dalenbäck J, Snel P et al (1996) Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334: 1018–1022PubMedCrossRefGoogle Scholar
  39. 39.
    Tatsuta M, Iishi H, Nakaizumi A, Okuda S, Taniguchi H, Hiyama T et al (1993) Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer 53: 70–74PubMedCrossRefGoogle Scholar
  40. 40.
    Cheli R, Santi L, Ciancarmerla G, Canciani G (1973) A clinical and statistical follow-up study of atrophie gastritis. Am J Dig Dis 18: 1061–1065PubMedCrossRefGoogle Scholar
  41. 41.
    Eissele R, Brunner G, Simon B, Solcia E, Arnold R (1997) Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 113: 2018–2019Google Scholar
  42. 42.
    Berstad AE, Hatlebakk JG, Maartmann-Moe H, Bestad A, Brandtzaeg P (1997) Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 41: 740–747PubMedCrossRefGoogle Scholar
  43. 43.
    Schenk BE, Kuipers EJ, Nelis GF, Thijs JC, Bloemena E, Snel P, Luckers P, Klinkenberg-Knol EC, Festen PP, Viergever PP et al (1998) H. pylori eradication for chronic gastritis during omeprazole therapy for GERD. Gastroenterology 114: A279CrossRefGoogle Scholar
  44. 44.
    Brunner G, Harke U (1994) Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 8 (Suppl 1): 59–64PubMedGoogle Scholar
  45. 45.
    Lundell L, Havu N, Andersson A, Miettienen P, Myrvold HE, Pedersen SA, Thor K (1997) Gastritis development and acid suppression therapy revisited. Results of a randomised clinical study with long-term follow-up. Gastroenterology 112: A28Google Scholar
  46. 46.
    Genta RM (1997) Helicobacter pylori, inflammation, mucosal damage and apoptosis: pathogenesis and definition of gastric atrophy. Gastroenterology 113: S51–S55PubMedCrossRefGoogle Scholar
  47. 47.
    Filipe MI, Muñoz N, Matko I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T (1994) Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57: 324–329PubMedCrossRefGoogle Scholar
  48. 48.
    Havu N (1998) Gastric morphology during long-term omeprazole therapy. Gastroenterology 114:A145CrossRefGoogle Scholar
  49. 49.
    Mart ínek J, Koelz HR, Blum AL (1997) Säureforschung und Ulkustherapie. Arzneim-Forsch/Drug Res 47(II): 1424–1435Google Scholar
  50. 50.
    Pantoflickova D, Mart ínek J, Blum AL. Safety and potential hazards of long-term inhibition of gastric acid secretion. Drug Safety;in press Google Scholar
  51. 51.
    Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Hakanson R, Olbe L, Solcia E, Walsh JH, Wolfe MM (1995) Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. Dig Dis Sci 40: 50S–62SPubMedCrossRefGoogle Scholar
  52. 52.
    Appelmelk BJ, Negrini R (1997) Helicobacter pylori and gastric autoimmunity. Curr Opin Gastroenterol 13: 31–34CrossRefGoogle Scholar
  53. 53.
    Sachs G, Wallmark B (1989) Biological basis of omeprazole therapy. J Gastroenterol Hepatol 4 (Suppl 2): 2–18Google Scholar
  54. 54.
    Sachs G, Scott D (1990) Cell digestion and genotoxicity assessment in gastric mucosa. Digestion 47 (Suppl 1): 31–34PubMedCrossRefGoogle Scholar
  55. 55.
    Eidt S, Lorenzen J, Ortmann M (1996) Depth of infiltration of primary gastric B-cell lymphomas-correlation with proliferation, apoptosis and expression of p53 and bcl-2. Pathol Res Pract 192: 925–930PubMedCrossRefGoogle Scholar
  56. 56.
    Wu MS, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT (1997) Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage and Helicobacter pylori infection. Gastroenterology 112: 1457–1465PubMedCrossRefGoogle Scholar
  57. 57.
    Farinati F, Delia Libera G, Cardin R, Molari A, Plebani M, Rugge M, Di Mario F, Naccarato R (1996) Gastric antioxidant, nitrites and mucosal lipoperoxidation in chronic gastritis and Helicobacter pylori infection. J Clin Gastroenterol 22: 275–281PubMedCrossRefGoogle Scholar
  58. 58.
    Fuchs CS, Mayer RJ (1995) Gastric carcinoma. N Engl J Med 333: 32–41PubMedCrossRefGoogle Scholar
  59. 59.
    Mowat C, Carswell A, McColl KEL (1998) Omeprazole lowers gastric juice ascorbic acid and elevates gastric juice nitrite concentrations. Gastroenterology 114: A236CrossRefGoogle Scholar
  60. 60.
    Verdu E, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, Idström J-P, Cederberg C, Blum AL, Fried M (1994) Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites and N-nitroso compounds. Gut 35: 455–460PubMedCrossRefGoogle Scholar
  61. 61.
    Thorens J, Froehlich F, Schwitzer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL (1996) Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 39: 54–59PubMedCrossRefGoogle Scholar
  62. 62.
    Pignatelli B, Malaveille C, Rogatko A, Hautefeuille A, Thuillier P, Muñoz N et al (1993) Mutagens, N-nitroso compounds and their precursors in gastric juice from patients with and without precancerous lesions of the stomach. Eur J Cancer 29A: 2031–2039PubMedCrossRefGoogle Scholar
  63. 63.
    Moss SF, Calam J, Agarwal B, Wang S, Holt PR (1996) Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 38: 498–501PubMedCrossRefGoogle Scholar
  64. 64.
    Jackson LM, Wu K, Mahida YR, Jenkins D, Donnelly MT, Hawkey CJ (1998) COX-1 expression in human gastric mucosa infected with Helicobacter pylori: constitutive or induced? Gastroenterology 114: A160CrossRefGoogle Scholar
  65. 65.
    Carlsson R, Bate C, Dent J, Frison L, Gnarpe H, Hallerbäck B, Unge P, LundellL (1998) Does H. pylori infection influence the response to treatment with acid inhibition in patients with gastroesophageal reflux disease? In: R Carlsson: Gastroesophageal reflux disease: a study of pathophysiology, clinical diagnosis and management. University of Göteborg, 61-72}Google Scholar
  66. 66.
    Holtmann G, Cain CR, Malfertheiner P (1998) The impact of H. pylori on healing of reflux esophagitis during treatment with pantoprazole. Gastroenterology 114: A151Google Scholar
  67. 67.
    Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, Van Rensburg CJ, Swannell AJ, Hawkey CJ (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338: 719–726PubMedCrossRefGoogle Scholar
  68. 68.
    Stok DL, Williams JG (1991) Alkaline reflux oesophagitis. Gut 32: 1090–1092CrossRefGoogle Scholar
  69. 69.
    Hudson N, Balsitis M, Filipowicz F, Hawkey CJ (1993) Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal antiinflammatory drugs. Gut 34: 748–751PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 1999

Authors and Affiliations

  • Andre Louis Blum
    • 1
  • Jan Martinek
    • 1
  1. 1.Division de Gastro-EnterologieChuvSwitzerland

Personalised recommendations